NEW ORLEANS — Izokibep, a novel interleukin-17 inhibitor, has shown dramatic responses in hidradenitis suppurativa treatment in an early phase 2 study, according to a speaker at the American Academy of Dermatology Annual Meeting.“[Hidradenitis suppurativa (HS)] is a horrible, horrible disease with a high disease burden. It’s extremely disruptive to anyone’s personal
NEW ORLEANS — Patients with psoriasis who had suboptimal results with prior interleukin-17 therapy experienced beneficial results with risankizumab, according to a presenter at the American Academy of Dermatology Annual Meeting.
“Within the real world, patients with residual disease really want to switch onto more effective therapy,” Richard B. Warren, MBChB, PhD, of the
NEW ORLEANS — A novel monoclonal antibody could be a promising treatment for hidradenitis suppurativa as phase 2 clinical trial results showed an improvement in total abscess and nodule count after 16 weeks of treatment.
Eltrekibart (LY3041658, Eli Lilly) is a humanized monoclonal antibody that binds to the seven ligands that signal through CXCR1 and CXCR2, according to Seth Forman, MD,
NEW ORLEANS — Symptoms of prurigo nodularis were significantly improved after 16 weeks of monotherapy with nemolizumab, according to a presenter at the American Academy of Dermatology Annual Meeting.“Prurigo nodularis, PN, is characterized by these intensely itchy nodules that are commonly on the extremities and the trunk,” Shawn G. Kwatra, MD, associate professor of dermatology
NEW ORLEANS — Phase 3 trial results found delgocitinib cream to significantly improve patient and clinician-reported outcomes of hand eczema, according to a presenter at the American Academy of Dermatology Annual Meeting.“Chronic hand eczema is one of the most frequent and chronic inflammatory disorders affecting hands,” Robert Bissonnette, MD, MSc, CEO and medical director of